Preferred Label : Sustained-Exposure Dexamethasone Formulation OTO-104;
NCIt synonyms : Sustained Release Dexamethasone Formulation OTO-104; Dexamethasone Sustained-exposure Formulation OTO-104; SR DXM Formulation OTO-104;
NCIt definition : A sustained-release (SR) poloxamer hydrogel formulation containing the glucocorticoid
dexamethasone (DXM), with potential otoprotective and anti-apoptotic activities. Prior
to the administration of an ototoxic drug and upon intratympanic (IT) injection of
the DXM sustained-exposure formulation OTO-104, DXM is slowly released from the hydrogel
over time; DMX then binds to glucocorticoid nuclear receptors, and activates cell
survival pathways. This prevents ototoxic drug-induced generation of reactive oxygen
species (ROS) by activating anti-oxidant enzymes, blocking the activation of inflammatory
cytokines and inducing stress signaling pathways, which ultimately prevents apoptosis
of auditory hair cells in the inner ear compartment. This prevents or reduces drug-induced
ototoxicity caused by certain therapeutic agents, such as platinum-based anticancer
agents. This may reduce or prevent hearing loss, tinnitus, and vertigo. The SR formulation
provides increased concentrations of DXM in the inner ear and maintains the elevated
levels for a longer time without the need of the multiple IT injections needed when
using non-SR DXM formulations. This agent also reduces the symptoms of certain ear-related
disorders.;
Molecule name : OTO-104;
NCI Metathesaurus CUI : CL520548;
Origin ID : C132014;
UMLS CUI : C4331365;
Semantic type(s)
- concept_is_in_subset
- has_target
